ライフサイエンスコーパス: delayed-type

1 tic ablation of NOX activity had reduced and delayed type 1 diabetes compared with NOD mice.

2 Systemic treatment of NOD mice significantly delayed type 1 diabetes onset.

3 ccination accelerated and CtfrII vaccination delayed type 1 diabetes.

4 bjects also exhibited a blunted and somewhat delayed type 1 T cell response to influenza vaccination,

5 erely impaired in IL-25(-/-) mice, including delayed type 2 cytokine responses, an attenuated functio

6 Delayed-type beta-lactam hypersensitivity develops in su

7 tact hypersensitivity (CHS) in the skin is a delayed type cellular immune response that can be mediat

8 suppression as measured by the inhibition of delayed type contact hypersensitivity to the chemical di

9 inflammation and hypersensitivity as well as delayed-type contact hypersensitivity were attenuated in

10 In contrast, delayed-type cutaneous hypersensitivity, a prototypic Th

11 ranscriptase inhibitor often inducing severe delayed-type drug hypersensitivity, can trigger innate i

12 model to study the pathologic role of HLA in delayed-type drug hypersensitivity.

13 Suppression of delayed type hypersensitivity (DTH) and in vivo lymphopr

14 tion correlates with a strong induction of a delayed type hypersensitivity (DTH) response following e

15 Maternal exposure to dLAN dampened delayed type hypersensitivity (DTH) responses in male of

16 IMP-1 and TIMP-2 had differential effects on delayed type hypersensitivity (DTH) responses to donor a

17 In this study, we show that cutaneous delayed type hypersensitivity (DTH) responses to recall

18 bined immunodeficiency mice to measure human delayed type hypersensitivity (DTH) responses.

19 T-cell (proliferation and delayed type hypersensitivity [DTH]) and B-cell (antibod

20 tivity, and cytokine production in vitro and delayed type hypersensitivity and inflammatory bowel dis

21 onor-specific regulation (DSR) by trans-vivo delayed type hypersensitivity assay at the time of enrol

22 rs before transplant and used the trans-vivo-delayed type hypersensitivity assay to measure immune re

23 The transvivo delayed type hypersensitivity assay was used to analyze

24 transplants as responders in the trans vivo-delayed type hypersensitivity assay, we found that dendr

25 Several models, including delayed type hypersensitivity in immune mice, and sponta

26 rotein showed potent in vivo efficacy in the delayed type hypersensitivity in rats.

27 f systemically activated T cells home to the delayed type hypersensitivity reaction induced by the ov

28 tenuated in subjects who are able to mount a delayed type hypersensitivity reaction to M. tuberculosi

29 s on ITK, which reduces an oxazolone-induced delayed type hypersensitivity reaction.

30 quisition of the capacity to mount cutaneous delayed type hypersensitivity reactions that disappeared

31 K14-mOVA Tg mice failed to mount T cell and delayed type hypersensitivity reactions to OVA, suggesti

32 global immunity as reflected by an enhanced delayed type hypersensitivity response and a 1.7-fold im

33 rechallenge prevented the development of the delayed type hypersensitivity response in vivo.

34 allogeneic tumor cells or the suppression of delayed type hypersensitivity responses against soluble

35 In addition, delayed type hypersensitivity responses are strongly imp

36 Analysis by transvivo delayed type hypersensitivity showed that the reactivity

37 n a mucosal tolerization schedule suppressed delayed type hypersensitivity to E-selectin confirming t

38 proliferation of T(EM) cells and suppresses delayed type hypersensitivity when administered at 10 or

39 liferation of human TEM cells and suppresses delayed type hypersensitivity, a TEM cell-mediated react

40 me-linked immunosorbent assay, Western blot, delayed type hypersensitivity, and enzyme-linked immunos

41 In the mouse model of delayed type hypersensitivity, we have shown an essentia

42 autoreactive anti-MPO CD4(+) cells to induce delayed type hypersensitivity-like necrotizing glomerula

43 gal and inhibited the ear-swelling assay for delayed type hypersensitivity.

44 expression of the IL-2 receptor and promoted delayed type hypersensitivity.

45 antibodies and histopathologic, RT-PCR, and delayed-type hypersensitivity (DTH) analyses were used t

46 ompanied by vigorous cardiac myosin-specific delayed-type hypersensitivity (DTH) and antibody product

47 these mice developed cardiac myosin-specific delayed-type hypersensitivity (DTH) and autoantibodies i

48 st skin-infiltrating lymphocytes in allergic delayed-type hypersensitivity (DTH) and bacterial chancr

49 acy of JAK-3 inhibitors was determined using delayed-type hypersensitivity (DTH) and collagen-induced

50 e absence of injury, aged mice had depressed delayed-type hypersensitivity (DTH) and splenocyte proli

51 In 14 of 14 patients, delayed-type hypersensitivity (DTH) and/or CD4 prolifera

52 Delayed-type hypersensitivity (DTH) assays demonstrate t

53 , interleukin-2-induced pulmonary edema, and delayed-type hypersensitivity (DTH) in mice.

54 s mediate the suppression of donor-specific, delayed-type hypersensitivity (DTH) in tolerant organ tr

55 both in vitro and in vivo in an Ag-specific delayed-type hypersensitivity (DTH) model in the cynomol

56 The effects of age, sex, and prevaccination delayed-type hypersensitivity (DTH) on the time course o

57 positive (responsive) or negative (anergic), delayed-type hypersensitivity (DTH) reaction to intrader

58 Safety, toxicity, delayed-type hypersensitivity (DTH) reaction, and induct

59 ntigen is injected, resulting in a classical delayed-type hypersensitivity (DTH) reaction.

60 All lesions were caused by allergic delayed-type hypersensitivity (DTH) reactions and not by

61 Delayed-type hypersensitivity (DTH) reactions elicited b

62 tory lymphokine essential for elicitation of delayed-type hypersensitivity (DTH) reactions in vivo.

63 the selectins play a role and predominate in delayed-type hypersensitivity (DTH) reactions of the ski

64 Systemic exposure to LTA or CPAF inhibited delayed-type hypersensitivity (DTH) reactions to the che

65 l inflammatory diseases including psoriasis, delayed-type hypersensitivity (DTH) reactions, and rheum

66 eumatoid arthritis, psoriasis, and cutaneous delayed-type hypersensitivity (DTH) reactions.

67 iphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions.

68 e and central memory subsets and inhibit the delayed-type hypersensitivity (DTH) response caused by s

69 o sand fly saliva in rodents induces a T(H)1 delayed-type hypersensitivity (DTH) response conferring

70 val, adverse events (AEs), and the effect of delayed-type hypersensitivity (DTH) response on clinical

71 There was a significant delayed-type hypersensitivity (DTH) response to adjuvant

72 /6 mice with indoles (I3C or DIM) attenuated delayed-type hypersensitivity (DTH) response to methylat

73 plex virus type 1 (HSV-1) develop a vigorous delayed-type hypersensitivity (DTH) response upon intrad

74 ized severe C. pneumoniae disease as being a delayed-type hypersensitivity (DTH) response with increa

75 antigen-specific proliferation in vitro, the delayed-type hypersensitivity (DTH) response, and serum

76 uppression in septic patients is an impaired delayed-type hypersensitivity (DTH) response, manifested

77 cterium bovis-specific antigens to stimulate delayed-type hypersensitivity (DTH) responses in cattle

78 n PPD were tested for the capacity to induce delayed-type hypersensitivity (DTH) responses in H37Rv-i

79 mmune cell infiltration at vaccine sites and delayed-type hypersensitivity (DTH) responses to autolog

80 Previously, we reported postvaccination delayed-type hypersensitivity (DTH) responses to autolog

81 The delayed-type hypersensitivity (DTH) responses to intrade

82 disease had high IgG antibody titers and no delayed-type hypersensitivity (DTH) responses to Leishma

83 mmunity, we hypothesized that decreased skin delayed-type hypersensitivity (DTH) responses to recall

84 to induce efferent T reg cells and suppress delayed-type hypersensitivity (DTH) responses.

85 ng, in vitro peptide recognition assays, and delayed-type hypersensitivity (DTH) responses.

86 y the degree of inflammation elicited during delayed-type hypersensitivity (DTH) responses.

87 ns ESAT-6, CFP-10, MPB70, and MPB83 elicited delayed-type hypersensitivity (DTH) skin test responses

88 Delayed-type hypersensitivity (DTH) testing in vivo and

89 egimen suppressed the strong myosin-specific delayed-type hypersensitivity (DTH) that normally develo

90 Patients were tested for delayed-type hypersensitivity (DTH) to autologous melano

91 polygyrus infection reduced the magnitude of delayed-type hypersensitivity (DTH) to PPD in the skin.

92 The challenged WT mice developed delayed-type hypersensitivity (DTH) to SEA; high levels

93 termined in a newly developed mouse model of delayed-type hypersensitivity (DTH) to sMRBC.

94 rfered with cell-mediated immunity as myosin delayed-type hypersensitivity (DTH) was reduced, while a

95 ssential mediators of autoimmune disease and delayed-type hypersensitivity (DTH), a convenient model

96 t survival, graft infiltration, allospecific delayed-type hypersensitivity (DTH), and cytokine expres

97 uble RAGE treatment is effective in reducing delayed-type hypersensitivity (DTH), even in RAGE(-/-) m

98 responsiveness by the ear-swelling test for delayed-type hypersensitivity (DTH), in vitro proliferat

99 Delayed-type hypersensitivity (DTH), suggesting T-cell r

100 This process resulted in a delayed-type hypersensitivity (DTH)-like EAE lesion.

101 were confirmed in vivo in a murine model of delayed-type hypersensitivity (DTH).

102 mals were unresponsive to PLP as measured by delayed-type hypersensitivity (DTH).

103 n and prevent the generation of allospecific delayed-type hypersensitivity (DTH).

104 ked the effects of UV in vivo and suppressed delayed-type hypersensitivity (DTH).

105 e differed from wild-type in the severity of delayed-type hypersensitivity (edema, T-cell and neutrop

106 In the delayed-type hypersensitivity (model 1), the HLA-DQ8 tra

107 velopment of specific antibody (P = .025) or delayed-type hypersensitivity (P = .03) responses to EGF

108 atic acid phosphatase (PAP) and a trans-vivo delayed-type hypersensitivity (tvDTH) assay, we found th

109 ic VL, (ii) asymptomatic infection (positive delayed-type hypersensitivity [DTH+]), or (iii) no evide

110 tein 60 was the only antigen shown to induce delayed-type hypersensitivity among other antigens teste

111 eactive T cells by ELISPOT and by trans-vivo delayed-type hypersensitivity analysis in a surrogate mu

112 Immunologic response was monitored by delayed-type hypersensitivity and [(3)H]thymidine prolif

113 HHE) associated with salutary or detrimental delayed-type hypersensitivity and AIDS phenotypes, respe

114 or in vivo inhibition, causing enhanced skin delayed-type hypersensitivity and antigen (Ag)-induced a

115 s several type 1 immune responses, including delayed-type hypersensitivity and autoimmunity in which

116 T cell responses and reduced inflammation in delayed-type hypersensitivity and clinical disease in EA

117 lammation and autoimmunity, murine models of delayed-type hypersensitivity and collagen-induced arthr

118 A in the a.c. displayed reduced OVA-specific delayed-type hypersensitivity and CTL responses, compare

119 ific mAb inhibited T cell-mediated models of delayed-type hypersensitivity and experimental autoimmun

120 Skin delayed-type hypersensitivity and experimental autoimmun

121 Furthermore, allospecific delayed-type hypersensitivity and gene expression of int

122 Delayed-type hypersensitivity and humoral immune respons

123 f AnxA1 also increased OVA-induced cutaneous delayed-type hypersensitivity and IFN-gamma and IL-17 re

124 lin epitope-specific Th1 effector functions (delayed-type hypersensitivity and IFN-gamma production)

125 ducing T lymphocyte-mediated inflammation in delayed-type hypersensitivity and in experimental autoim

126 Contact sensitivity (CS) is related to delayed-type hypersensitivity and is a well-characterize

127 reated mice, as indicated by reduced in vivo delayed-type hypersensitivity and reduced levels of sple

128 icking to draining lymph nodes, induction of delayed-type hypersensitivity and rejection of corneal t

129 age-related T cell dysfunction, Ag-specific delayed-type hypersensitivity and T cell proliferation w

130 n control IgG exhibited impaired Ag-specific delayed-type hypersensitivity and T cell proliferation,

131 that excessive activity of T cells mediates delayed-type hypersensitivity and that cellular cytolysi

132 Chlamydial delayed-type hypersensitivity antigens were analyzed by

133 tic capacity of uPA in the CIA model and the delayed-type hypersensitivity arthritis model.

134 reduced arthritis progression in the CIA and delayed-type hypersensitivity arthritis models.

135 Techniques, such as the trans vivo delayed-type hypersensitivity assay, ELISPOT and antigen

136 MSCs was studied in vivo in a mouse model of delayed-type hypersensitivity assay.

137 al blood of 45 patients using the trans-vivo delayed-type hypersensitivity assay.

138 from C57BL/6 CD4 KO mice were assessed using delayed-type hypersensitivity assays and Annexin V apopt

139 Delayed-type hypersensitivity assays demonstrated that i

140 Mixed-lymphocyte reactions and delayed-type hypersensitivity assays were performed to e

141 21 significantly enhanced the Th1-associated delayed-type hypersensitivity cutaneous responses.

142 HER2-specific delayed-type hypersensitivity developed in most patients

143 ection against disseminated candidiasis, but delayed-type hypersensitivity did.

144 immunopathology was found to be operative in delayed-type hypersensitivity footpad-swelling reaction

145 these cells to present Ag for elicitation of delayed-type hypersensitivity in previously immunized mi

146 of Th2 enhancement, as indicated by reduced delayed-type hypersensitivity in the context of enhanced

147 to inhibit T-cell proliferation and control delayed-type hypersensitivity in vivo.

148 press the keyhole limpet hemocyanin-specific delayed-type hypersensitivity inflammatory response.

149 sessment of Th1 function using the cutaneous delayed-type hypersensitivity model confirmed that p53(-

150 stopathological analysis of tissues from the delayed-type hypersensitivity model demonstrates that in

151 ed CD4(+) T-cell immune response in a murine delayed-type hypersensitivity model in vivo.

152 (+) T cell responses were also observed in a delayed-type hypersensitivity model in which mTORC2 was

153 In a delayed-type hypersensitivity model, both T cell infiltr

154 able to reduce inflammation in a murine paw delayed-type hypersensitivity model, suppress the onset

155 ted anti-inflammatory properties in a murine delayed-type hypersensitivity model.

156 a T cells do not cause direct suppression of delayed-type hypersensitivity nor do they act as tolerog

157 hat disease is mediated by antigen-dependent delayed-type hypersensitivity or autoimmunity.

158 compound showed good efficacy in an in vivo delayed-type hypersensitivity pharmacology model in rats

159 nodes (LNs) of mice with cOVA-induced airway delayed-type hypersensitivity reaction (DTHR) but not in

160 king RON exhibit increased inflammation in a delayed-type hypersensitivity reaction and increased sus

161 In a delayed-type hypersensitivity reaction in vivo, compound

162 A delayed-type hypersensitivity reaction test was administ

163 el of experimentally induced peritonitis and delayed-type hypersensitivity reaction.

164 easured from inhibition of ear swelling in a delayed-type hypersensitivity reaction.

165 However, severe delayed-type hypersensitivity reactions (DHR) induced by

166 d with E. chaffeensis, the animals developed delayed-type hypersensitivity reactions at cutaneous sit

167 naling of human T cells in vitro and reduces delayed-type hypersensitivity reactions in rats in vivo.

168 terolemia is frequent in these patients, and delayed-type hypersensitivity reactions in the arterial

169 TIGIT-Fc inhibited delayed-type hypersensitivity reactions in wild-type but

170 ve indicated that UVB-mediated inhibition of delayed-type hypersensitivity reactions is mediated, in

171 Posttreatment induction of delayed-type hypersensitivity reactions to autologous le

172 Patients have developed delayed-type hypersensitivity reactions to E75 postvacci

173 Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, d

174 Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, d

175 2) in the control of cutaneous inflammation, delayed-type hypersensitivity reactions were elicited in

176 e responses against intracellular pathogens, delayed-type hypersensitivity reactions, and induction o

177 d exhibited normal T cell priming and normal delayed-type hypersensitivity reactions.

178 han of PPD were needed to induce substantial delayed-type hypersensitivity reactions.

179 ce compared with wild-type littermates after delayed-type hypersensitivity reactions.

180 ine known to be essential for development of delayed-type hypersensitivity reactions.

181 showed that IL-27 regulated the severity of delayed-type hypersensitivity response and EAE through i

182 icance of the role of IL-27 was addressed in delayed-type hypersensitivity response and experimental

183 ignificantly stronger CD4(+) T-cell-mediated delayed-type hypersensitivity response and resulted in s

184 ry effect of alpha(1)beta(1) blockade on the delayed-type hypersensitivity response could be bypassed

185 owever, IL-10-deficient mice had an enhanced delayed-type hypersensitivity response during the chroni

186 ed allografts did not elicit an alloreactive delayed-type hypersensitivity response in graft recipien

187 VIP inhibited elicitation of a delayed-type hypersensitivity response in previously imm

188 fluence of photoperiod and acute stress on a delayed-type hypersensitivity response in the skin.

189 In a pattern-I-type delayed-type hypersensitivity response model, a similar

190 Inhibition of the delayed-type hypersensitivity response required that the

191 IL-10 transgenic mice demonstrated a smaller delayed-type hypersensitivity response to allogeneic cel

192 lymph nodes and allografts, 2) a suppressed delayed-type hypersensitivity response to B6D2F1 Ags, an

193 rative responses and a significantly reduced delayed-type hypersensitivity response to challenge anti

194 trates demonstrated a much weaker peripheral delayed-type hypersensitivity response to donor alloanti

195 et KO cells, gastritis was associated with a delayed-type hypersensitivity response to H. pylori anti

196 Lastly, P763.74, but not PGH786, induced a delayed-type hypersensitivity response to HMW-MAA-bearin

197 spleen T cells in vitro and inhibition of a delayed-type hypersensitivity response to oxazolone in v

198 on-induced immunosuppression, resulting in a delayed-type hypersensitivity response to photo-induced

199 -MEM mice responded with an enhanced footpad delayed-type hypersensitivity response, and more IFN-gam

200 lin E and inhibition of the anticryptococcal delayed-type hypersensitivity response, indicating a shi

201 t not CpG 1826/IFA as an adjuvant elicited a delayed-type hypersensitivity response.

202 nths), and recurrence correlated with a weak delayed-type hypersensitivity response.

203 condary infection, and exhibited an impaired delayed-type hypersensitivity response.

204 onsequently, these cells failed to sustain a delayed-type hypersensitivity response.

205 rdiac myosin (autoimmunity) but did decrease delayed-type hypersensitivity responses against both ant

206 , characterized by Ag-specific inhibition of delayed-type hypersensitivity responses and a reduction

207 n the periphery, which resulted in increased delayed-type hypersensitivity responses and autoimmune d

208 ACAID is characterized by decreases in delayed-type hypersensitivity responses and complement-f

209 Our data demonstrate that decorin modulates delayed-type hypersensitivity responses by augmenting th

210 induced Ag-specific T cell proliferation and delayed-type hypersensitivity responses in FcgammaRIIB-e

211 orphisms and haplotype pairs that influenced delayed-type hypersensitivity responses in healthy perso

212 reduced IFN-gamma production, and inhibited delayed-type hypersensitivity responses in immune mice c

213 ls, which failed to undergo proliferative or delayed-type hypersensitivity responses in recipients.

214 ma tumor cells, and tumor-loaded DC1s induce delayed-type hypersensitivity responses in vivo.

215 zation, because Jak3-/- chimeric mice showed delayed-type hypersensitivity responses indistinguishabl

216 administration of MSCs significantly reduced delayed-type hypersensitivity responses to allogeneic an

217 Delayed-type hypersensitivity responses to C57BL/6 alloa

218 ermined by the level of serum antibodies and delayed-type hypersensitivity responses to HMW-MAA-beari

219 yeloperoxidase CD4+ T cells, enhanced dermal delayed-type hypersensitivity responses to myeloperoxida

220 Liver but not spleen pDCs suppress delayed-type hypersensitivity responses to OVA, an effec

221 Furthermore, 139-iTregs inhibit delayed-type hypersensitivity responses to PLP139-151, b

222 n 42 patients with leprosy were compared for delayed-type hypersensitivity responses to purified prot

223 ount but was associated with higher rates of delayed-type hypersensitivity responses to TT (25% of su

224 of murine CD8(+) dendritic cells to suppress delayed-type hypersensitivity responses to tumor-associa

225 Baseline delayed-type hypersensitivity responses were enhanced du

226 41 vaccination decreased corneal opacity and delayed-type hypersensitivity responses while elevating

227 combinant murine IL-10 were able to suppress delayed-type hypersensitivity responses within injected

228 We used cutaneous delayed-type hypersensitivity responses, a powerful in v

229 Cs including enhanced T-cell reconstitution, delayed-type hypersensitivity responses, and class-switc

230 nterferon gamma-producing T cells, increased delayed-type hypersensitivity responses, and higher seru

231 es: rash, high fever, viremia, depression of delayed-type hypersensitivity responses, lowered leukocy

232 not age, was associated with impairments in delayed-type hypersensitivity responses, lymphoprolifera

233 ed bystander suppression of tetanus-specific delayed-type hypersensitivity responses, which was rever

234 rvival demonstrated prominent donor-reactive delayed-type hypersensitivity responses, which were incr

235 G(35-55) in vitro and demonstrated decreased delayed-type hypersensitivity responses.

236 They had significant leukopenia and reduced delayed-type hypersensitivity responses.

237 sitivity and enhancement of antigen-specific delayed-type hypersensitivity responses.

238 corin modulates leukocyte recruitment during delayed-type hypersensitivity responses.

239 cross-regulation of Th1 cells or exaggerated delayed-type hypersensitivity responses.

240 tor and memory T cells inhibited Ag-specific delayed-type hypersensitivity responses; similar decreas

241 ed antigen-specific T-cell proliferation and delayed-type hypersensitivity skin response.

242 Delayed-type hypersensitivity skin test responses were m

243 ral load, baseline CD4(+) T cell counts, and delayed-type hypersensitivity skin test responses, an in

244 assessed by in vitro proliferation assay and delayed-type hypersensitivity skin testing.

245 Delayed-type hypersensitivity skin tests showed that som

246 induced by IFN-gamma, TNF, TLR agonists, and delayed-type hypersensitivity than CCR4(-) cells.

247 s II expression on macrophages, and restored delayed-type hypersensitivity to a model hapten, consist

248 hermore, ATPgammaS enhanced the induction of delayed-type hypersensitivity to a model tumor vaccine i

249 in the hosts and inhibited the expression of delayed-type hypersensitivity to donor alloantigens.

250 BALB/c mice with pre-established delayed-type hypersensitivity to hen OVA were immunized

251 of healthy subjects have tested positive for delayed-type hypersensitivity to soluble leishmania anti

252 ed immunologic memory and the elicitation of delayed-type hypersensitivity to the common opportunisti

253 filtrates responded strongly to donor Ags in delayed-type hypersensitivity trans-vivo assays.

254 vels of inflammation were seen in a model of delayed-type hypersensitivity using 2,4-dinitrofluoroben

255 Additionally, allospecific delayed-type hypersensitivity was compared among the gro

256 Delayed-type hypersensitivity was enhanced in women with

257 The correlations of increased delayed-type hypersensitivity with -2459G/G-containing C

258 nd gastric epithelial metaplasia), cellular (delayed-type hypersensitivity) and humoral immune respon

259 reactions triggered by immune (immediate and delayed-type hypersensitivity) and non-immune (intoleran

260 Sixteen subjects (out of 315 with CS delayed-type hypersensitivity) presented with allergic m

261 beta1AR(-/-) mice had improved cellular (delayed-type hypersensitivity) responses while beta2AR(-

262 nted a hallmark of sepsis (i.e., the loss of delayed-type hypersensitivity), which is an IFN-gamma- a

263 ction of antigen inhibits the development of delayed-type hypersensitivity, a phenomenon known as ant

264 mice exhibited T cell priming by peptide and delayed-type hypersensitivity, although these responses

265 , MAS, mean and cumulative arthritis scores, delayed-type hypersensitivity, and antibody responses to

266 , suppress primarily Th1 responses including delayed-type hypersensitivity, and transfer suppression

267 nies many type 1 immune responses, including delayed-type hypersensitivity, autoimmunity, and graft r

268 Delayed-type hypersensitivity, CD4 and CD8 counts, anti-

269 Immune responses were evaluated by delayed-type hypersensitivity, CD4+ T-cell proliferation

270 In a more generalized model of inflammation, delayed-type hypersensitivity, CP-481,715 significantly

271 respect to disease induction, enhancement of delayed-type hypersensitivity, enhancement of lymphocyte

272 clude mixed lymphocyte reactions, trans-vivo delayed-type hypersensitivity, enzyme-linked immunospot

273 es of T cell function--ranging from positive delayed-type hypersensitivity, in asymptomatic infected

274 ain aspects of immune function, particularly delayed-type hypersensitivity, may be improved in HD pat

275 Using Ag-specific delayed-type hypersensitivity, T cell proliferation, and

276 lls and prevented these mice from developing delayed-type hypersensitivity, which is critically depen

277 nate immune activation to medication-induced delayed-type hypersensitivity, which may stimulate new c

278 nodes and to the inflamed paw in a model of delayed-type hypersensitivity.

279 cytokines associated with the development of delayed-type hypersensitivity.

280 r apoptotic activity using a murine model of delayed-type hypersensitivity.

281 rized by impairment of Th1 responses such as delayed-type hypersensitivity.

282 on (IFN-gamma), nitric oxide production, and delayed-type hypersensitivity.

283 ion of Th1 splenocytes and increased in vivo delayed-type hypersensitivity.

284 ion of macrophage influx in a mouse model of delayed-type hypersensitivity.

285 ogical exams and demonstration of leishmanin delayed-type hypersensitivity.

286 hocytes, as well as an inability to manifest delayed-type hypersensitivity.

287 te-induced peritonitis and oxazolone-induced delayed-type hypersensitivity.

288 immediate-type hypersensitivity; and reduced delayed-type hypersensitivity.

289 d induction of sepsis-induced suppression of delayed-type hypersensitivity.

290 of immunity by B. dendrobatidis, a modified delayed-type-hypersensitivity (DTH) protocol was develop

291 inished memory T-cell populations, decreased delayed-type-hypersensitivity responses and decreased in

292 It was effective in vivo at inhibiting the delayed type hypersensivity reaction in mice.

293 rum specific IgE antibodies to alpha-gal and delayed type I allergic reactions to the carbohydrate al

294 In addition, IRF-3-deficient BMDCs exhibited delayed type I IFN synthesis compared to control cells.

295 that robust virus replication accompanied by delayed type I interferon (IFN-I) signaling orchestrates

296 hypersensitivity (CHS) is a T cell-mediated delayed-type immune response which has been considered t

297 mechanism-mediated finding consistent with a delayed-type immune-mediated type IV hypersensitivity in

298 also been implicated in type IV (also termed delayed-type or T cell-mediated) hypersensitivity reacti

299 vity to corticosteroids is a common finding, delayed-type reactions being much more frequently encoun

300 Delayed-type, T cell-mediated, drug hypersensitivity rea